Summary
Bristol Myers Squibb (BMY) filed its 10-Q for the period ending June 29, 2024, on July 25, 2024. While the filing provides detailed financial statements and management's discussion, it does not contain the actual financial performance figures (revenue, net income, etc.) in the provided snippet. Investors should refer to the full filing for specific performance metrics. The document outlines the structure of the report, indicating sections covering financial statements, management's discussion and analysis, market risk, legal proceedings, risk factors, and other information. Key areas to scrutinize in the full report will include the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" for insights into the company's performance drivers, challenges, and strategic outlook. Investors should pay close attention to Item 1A, "Risk Factors," as it will detail any new or evolving risks that could impact BMY's future financial performance. The report's structure suggests a comprehensive review of the company's operations and financial health. The absence of specific financial data in the provided excerpt means a deeper dive into the full 10-Q is essential for investors to understand the quarter's financial results, cash flow generation, and overall financial position.
Financial Highlights
56 data points| Revenue | $12.20B |
| Cost of Revenue | $3.27B |
| Gross Profit | $8.93B |
| R&D Expenses | $2.90B |
| SG&A Expenses | $1.93B |
| Operating Expenses | $10.91B |
| Net Income | $1.68B |
| EPS (Basic) | $0.83 |
| EPS (Diluted) | $0.83 |
| Shares Outstanding (Basic) | 2.03B |
| Shares Outstanding (Diluted) | 2.03B |
Key Highlights
- 1The 10-Q filing covers the quarterly period ending June 29, 2024, and was filed on July 25, 2024.
- 2The filing includes standard SEC disclosure sections: Financial Statements, Management's Discussion and Analysis, Market Risk, Legal Proceedings, and Risk Factors.
- 3Investors are directed to the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" for detailed operational and financial insights.
- 4The "Risk Factors" section (Item 1A) is crucial for understanding potential headwinds and uncertainties facing Bristol Myers Squibb.
- 5The provided excerpt focuses on the structure and index of the 10-Q, not specific financial performance figures.
- 6The report signifies ongoing financial reporting and regulatory compliance for Bristol Myers Squibb.
- 7Trademark information for various products is noted as being included within the filing.